Revvity二季度业绩 beat 但一次性收益与生命科学疲软削弱交易价值

BofA says this memory stock could double. Here are 5 reasons why
Introduction & Market Context
Revvity (NYSE:RVTY) presented second-quarter 2026 results on August 4 that revealed a tale of two segments, with surging diagnostics performance offsetting continued weakness in life sciences. The company’s earnings presentation highlighted pro forma revenue of $711 million, up 4% year-over-year, and adjusted earnings per share of $1.41, representing 23% growth. However, investors focused on the quality of the beat, sending shares down 3.68% in premarket trading to $110.98 as roughly half the EPS upside stemmed from one-time tariff refunds and favorable tax timing.
The scientific solutions company, which helps customers solve health challenges from discovery through diagnosis, emphasized improving market conditions in pharma and biotech, strong diagnostic trends outside China, and the early stages of AI-driven transformation in drug discovery workflows.
Quarterly Performance Highlights
As shown in the following summary of second-quarter financial results, Revvity delivered performance above expectations across multiple metrics, though the composition of the beat raised questions about sustainability.
Pro forma revenue reached $711 million with 3% organic growth, slightly above the high end of guidance. The adjusted operating margin expanded significantly to 29.3%, up 280 basis points year-over-year, driven by volume leverage and operational efficiency initiatives. Adjusted gross margin improved 200 basis points to 62.3%, reflecting strong pricing power and favorable product mix.
The company generated $184 million in free cash flow during the quarter, bringing year-to-date cash generation to $299 million with 108% conversion of adjusted net income. This strong cash performance enabled Revvity to retire a €500 million note in mid-July, further strengthening the balance sheet.
Importantly, the presentation disclosed that pro forma adjusted operating income and EPS benefited by $16 million and approximately $0.11, respectively, from tariff-related refunds. This one-time benefit accounted for roughly half of the earnings upside relative to expectations, tempering enthusiasm about the core operational performance.
Segment Performance Analysis
The following breakdown illustrates how Revvity’s $711 million in quarterly revenue was distributed across segments, geographies, and product types, revealing the divergent performance trends.
The diagnostics segment emerged as the clear growth driver, while life sciences faced headwinds primarily from software timing issues. The geographic split showed strength in Europe and Asia-Pacific, while recurring revenue maintained solid growth in the high-single-digit range.
Examining the life sciences segment in detail, revenue of $359 million declined 2% on a reported basis and 3% organically, pressured by a sharp software decline.
The segment’s performance reflected mid-single-digit declines in pharma/biotech and low-single-digit declines in academic/government end markets, primarily due to software weakness. However, Life Sciences Solutions showed low-single-digit growth in both reagents and instruments. Software revenue fell approximately 20% organically due to contract renewal timing and difficult year-over-year comparisons. Adjusted operating margins compressed 50 basis points to 31.1% as software volume declines and strategic investments offset productivity gains.
In stark contrast, the diagnostics segment delivered robust growth and margin expansion.
Diagnostics revenue of $352 million grew 12% on a reported basis and 11% organically, with broad-based strength across the portfolio. Immunodiagnostics posted high-single-digit growth with contributions from multiple product lines, while Reproductive Health achieved double-digit growth driven by newborn screening and partnership revenue. Adjusted operating margins surged 520 basis points to 30.4%, benefiting from volume leverage, operational efficiency initiatives, and tariff refunds. Notably, the diagnostics margin performance included a 90-basis-point headwind from the China ImmunoDx business that the company has agreed to divest.
Strategic Initiatives
The company’s key takeaways for the quarter emphasized innovation, market improvements, and strong execution, as illustrated in the following summary.
On the innovation front, Revvity launched several AI-enabled products including Signals AI, the Signals Anthropic connector for integrating large language models into research workflows, and a new Signals for Startups program targeting smaller biotech companies. The company also received FDA clearance for its testosterone assay, expanding its diagnostic menu.
Management highlighted improving pharma and biotech end market conditions, particularly orders tied to AI-driven drug discovery platforms. Chief Executive Prahlad Singh described "tangible signs of a more constructive spending environment" with increasing demand from both traditional customers and newer entrants building AI-powered research capabilities. The company is positioning itself to capitalize on what executives called "lab-in-the-loop workflows" where AI models become integrated into the experimental cycle itself.
The definitive agreement to divest the China ImmunoDx business represents a strategic exit from a challenging market. The divestiture is expected to close by the end of 2027 and allows the company to present pro forma results that exclude this operation, providing clearer visibility into the core business trajectory.
Forward-Looking Statements
Revvity raised its full-year 2026 outlook across multiple metrics, reflecting confidence in second-half acceleration despite the mixed second-quarter results.
The company now expects pro forma revenue of $2.83 billion to $2.86 billion, representing 5% to 6% total growth and 4% to 5% organic growth, up from the prior range of 3% to 4% organic growth. The adjusted operating margin outlook increased 30 basis points to 28.7%, while adjusted EPS guidance rose to $5.30 to $5.40 from $5.20 to $5.30 previously.
For the third quarter, management guided to 4% to 6% organic growth, revenue of $685 million to $700 million, and adjusted operating margin of approximately 29%. The full-year outlook assumes stronger performance in reagents and instrumentation in the second half but does not assume further acceleration beyond current market conditions.
The guidance incorporates several key assumptions: continued improvement in pharma and biotech spending, sustained diagnostics momentum outside China, gradual recovery in software revenue from contract renewals and new product launches, and reinvestment of a portion of the tariff refund benefit into supply chain capacity and personnel.
Market Context and Valuation Considerations
Despite beating Wall Street expectations on both revenue and earnings, Revvity shares declined in premarket trading, suggesting investors were weighing the quality and sustainability of the results. The stock fell to $110.98, down from the previous close of $115.22, though it remained near the upper end of its 52-week range of $81.22 to $118.30.
Several factors likely contributed to the muted market reaction. First, the disclosure that approximately $0.11 of the $1.41 adjusted EPS came from one-time tariff refunds meant that roughly half the earnings beat was non-recurring. Second, the 3% organic growth rate, while above guidance, still reflects a business in early-stage recovery rather than robust expansion. Third, the life sciences segment’s 3% organic decline and 20% software drop underscore execution challenges in key growth areas.
The company’s valuation also leaves limited room for disappointment. Trading at a price-to-earnings ratio of 55.26, Revvity commands a premium multiple that requires consistent delivery of improving fundamentals. The high valuation reflects market expectations for the company to capitalize on secular trends in AI-driven drug discovery and precision diagnostics, but also means any stumbles in execution or guidance could trigger outsized stock reactions.
On a more positive note, the company’s balance sheet strengthened materially during the quarter. Net debt to adjusted EBITDA leverage stood at 2.5x at quarter-end and is expected to fall below 3x by year-end following the July retirement of the €500 million note. This deleveraging provides financial flexibility to invest in growth initiatives and pursue strategic opportunities.
The diagnostics segment’s 11% organic growth and 520-basis-point margin expansion demonstrate the company’s ability to execute in favorable end markets. If management can stabilize and eventually return the life sciences segment to growth—particularly as software renewals normalize and AI-related instrument demand builds—the combined portfolio could deliver more balanced and sustainable performance in coming quarters.
Investors will likely focus on several key questions in the months ahead: Can software revenue stabilize and return to growth as contract renewals progress? Will AI-related instrument orders translate into sustained reagent pull-through? Can diagnostics maintain double-digit growth rates, or will tougher comparisons slow the pace? And perhaps most importantly, can the company demonstrate that the second-quarter margin expansion reflects sustainable operational improvements rather than temporary benefits from tariff refunds and favorable mix?
The answers to these questions will determine whether Revvity can sustain its premium valuation and deliver on the promise of its positioning at the intersection of AI, life sciences, and diagnostics.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.